Skip to content

Piracetam

Also called Nootropil, Memotropil, Pirasmart — the 1964 parent of the racetam class

The molecule every other racetam on this site is a derivative of, and the one with no identified receptor after sixty years.

  • TypeSmall molecule
  • FormOral
  • Researched forCognitive & Mood

Where to get Piracetam

RUPharma
Oral
Code CAMERON

The only form sold. Research compound, not approved for human use.

Shop oral at RUPharma

The short version

  • Why people research itFocus, memory, neuroprotection, mood and stress resilience.
  • What the evidence isThe clearest controlled result is not a cognition result.
  • What to watchBlack stools, severe bruising or bleeding that is slow to stop.

How Piracetam works

Sixty years on, this molecule still has no identified receptor, and the way to say that usefully is to put its own descendant next to it. Levetiracetam is piracetam with an ethyl group on the acetamide carbon, made by the same company, and its FDA label names a target: “A saturable and stereoselective neuronal binding site in rat brain tissue has been described … this binding site is the synaptic vesicle protein SV2A” Keppra label 2026.

What the hypothesis actually claims, stated precisely enough to be wrong. Muller 1999 argues that piracetam does not bind a protein at all: it interacts with the polar head groups of the phospholipid bilayer and alters membrane fluidity. The distinctive part is the conditionality.

The mechanism on offer is physico-chemical rather than pharmacological: an interaction with the polar head groups of the phospholipid bilayer that alters membrane fluidity, reported as larger in aged brain membranes than young ones, with a mitochondrial extension — raised membrane potential and ATP production — proposed on top of it. Its own structural descendant, levetiracetam, does have a named target: the synaptic vesicle protein SV2A.

  • Oral

On the goal map: Cholinergic — attention, encoding & recall (Focus, memory & cognition)

Research on Piracetam8 evidence notes: clinical, correlative, mechanism

Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work

Evidence on file: Human trials — positive in cortical myoclonus; the Cochrane review for dementia and cognitive impairment does not support that use. Not approved in the US.

Human clinical evidence

  • The clearest controlled result is not a cognition result. A 21-patient double-blind placebo-controlled crossover in disabling myoclonus, almost all of cortical origin, at 2.4 to 16.8 grams daily: 10 of 21 had to be rescued from the placebo arm and none from the drug arm, with a median 22% improvement in total rating score (Brown 1993, Mov Disord).

  • The Cochrane review of piracetam for dementia or cognitive impairment does not support that use (Flicker & Grimley Evans 2001) — and it has not been updated since.

  • Not approved in the US. There is no DailyMed prescribing information for it, so there is no regulator-reviewed adverse-event table to quote. That is an absent safety record, not a clean one.

Correlative data

  • Which is a fraction of the only range with a controlled result behind it.

  • Market surveillance by 12 official medicines control laboratories across Europe and Australia found most nootropic samples came from the illegal market, with prescription drugs present in pharmacological quantities (Vanhee 2025).

How the mechanism reads

  • Sixty years and no identified receptor. The mechanism on offer is physico-chemical: interaction with phospholipid head groups altering membrane fluidity, reported as larger in aged brain membranes than young ones (Muller 1999), with a mitochondrial extension — raised membrane potential and ATP production — layered on top (Leuner 2010).

    Mechanistic
  • Its own descendant has the target it lacks. Levetiracetam is piracetam plus an ethyl group from the same company, and its label names a saturable, stereoselective binding site identified as SV2A. Nobody has run that assay on the parent.

    Mechanistic
  • The mechanism's own prediction cuts against retail use: a membrane effect that is larger in aged membranes should do less in a young healthy brain. Its advocates say so explicitly.

    Mechanistic

Sources

Piracetam safety basicsWho should avoid it, what to expect, what to watch

Avoid if

  • Severe kidney impairment: it is cleared unchanged by the kidney and accumulates.
  • Brain hemorrhage: the label lists it as a contraindication because it reduces platelet aggregation.
  • Huntington's chorea: the label advises against it.
  • Blood thinners: it lowers fibrinogen and platelet stickiness.
  • Pregnancy: piracetam crosses the placenta, and the label advises against it.

What’s expected

  • Often little noticeable effect, with membrane fluidity as its only proposed mechanism.
  • Nervousness, headache or trouble sleeping.
  • Weight gain or sleepiness in some users.
  • Easier bruising.

Watch for

  • Black stools, severe bruising or bleeding that is slow to stop.
  • Agitation or depression.
  • New tremor or uncontrolled movements.
  • Little urine.

Labs that tell you it’s working

  • Cystatin C with eGFR
  • Complete Blood Count (CBC) w/ Differential
  • Fibrinogen Activity
  • Comprehensive Metabolic Panel (CMP)

No identified receptor; proposed action is on membrane fluidity, with renal clearance and a mild antiplatelet effect as predicted harms. PMID 11405971 PMID 8419809 PMID 10338102

Also on the record

  • Not an approved drug in the US, so no regulator-reviewed adverse-event table exists for it.

Bloodwork to runHow you would know it is working: 8 tests in one order, code CAMERON

Piracetam FAQ4 common questions

Is Piracetam approved for human use?
No. Piracetam is a research compound.
What is Piracetam researched for?
Focus, memory, neuroprotection, mood and stress resilience.
Which labs show whether it's doing anything?
Cystatin C with eGFR; Complete Blood Count; Fibrinogen Activity; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
Where's the full protocol?
In the Skool lesson for Piracetam: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Protocol & dosing: inside Skool

This page covers what Piracetam is. Skool covers how it is run.

Free on this page

What Piracetam is and how it works · The research, labeled by the kind of evidence · Its own safety lines and the bloodwork panel

  • What Piracetam is and how it works
  • The research, labeled by the kind of evidence
  • Its own safety lines and the bloodwork panel

Members get

  • The reported research range, and how each number was reached
  • The protocols: what to run together, in what order, for how long and when to stop
  • The members' prep tool, and live Q&A with Cam every Tuesday
Join Skool $10/mo1,500+ members, 5.0 rating from 15 reviews. Cancel anytime.
The members' Prep Bench in Skool: the compound finder (no dose shown)
The members’ Prep Bench

Want it built around you?

The coaching app, with sample data

1-on-1 coaching with Cam

Your plan, your bloodwork and your check-ins, built around you.

Research Protocol $150/mo · Full Coaching $250/mo

See coaching

One question? Book a 15-minute consult

A call with Cam on the one thing you are stuck on.

$75 per call

Book a consult

Educational and research purposes only. Not medical advice. Research compounds are discussed for research use only, not human use. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer & affiliate disclosure

Buy with codeJoin Skool